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Cell therapy can improve cardiac function in animals
and humans after injury, but the mechanism is
unclear. We performed cell therapy experiments in
genetically engineered mice that permanently ex-
press green fluorescent protein (GFP) only in cardio-
myocytes after a pulse of 4-OH-tamoxifen. Myocar-
dial infarction diluted the GFP+ cardiomyocyte pool,
indicating refreshment by non-GFP+ progenitors.
Cell therapy with bone marrow-derived c-kit+ cells,
but not mesenchymal stem cells, further diluted the
GFP+ pool, consistent with c-kit+ cell-mediated
augmentation of cardiomyocyte progenitor activity.
This effect could not be explained by transdifferen-
tiation to cardiomyocytes by exogenously delivered
c-kit+ cells or by cell fusion. Therapy with c-kit+ cells
but not mesenchymal stem cells improved cardiac
function. These findings suggest that stimulation
of endogenous cardiogenic progenitor activity is a
critical mechanism of cardiac cell therapy.
INTRODUCTION
Adult mammalian cardiomyocytes retain some capacity for
renewal (Beltrami et al., 2003; Bergmann et al., 2009; Hsieh
et al., 2007), but this response is inadequate for prevention of
heart failure after cardiac injury (Lopez et al., 2006). Demonstra-
tionsof cardiomyocyte transdifferentiation bya variety of progen-
itor cells have provided the rationale for cell-therapy experiments
in animal models and in humans with heart failure (Segers and
Lee, 2008). Although some trials have shown improvements in
cardiac function after cellular therapies, the therapeutic effect
has been modest in most studies, and the mechanism of action
remains incompletely elucidated (Abdel-Latif et al., 2007).
A wide variety of mechanistic explanations for functional
benefits observedwith cardiac cell therapy have been proposed.
The direct transdifferentiation into cardiomyocytes by exoge-
nous cells represents the most obvious explanation for cell
therapy-mediated improvements in cardiac function, yet the
capacity for direct transdifferentiation by exogenously deliveredcells remains unclear (Balsam et al., 2004; Murry et al., 2004;
Orlic et al., 2001). Additional proposed mechanisms of cell
therapy include inflammatory modulation, transdifferentiation
into endothelial or smooth muscle cells, or paracrine stimulation
of angiogenesis or endogenous cardiomyocyte progenitors.
Defining the contributions of these mechanisms represents a
fundamental prerequisite to the future optimization of cardiac
regenerative therapies.
Genetically engineered mice enable lineage mapping experi-
ments to determine the role of progenitors in regenerative
processes. We previously described a double-transgenic
MerCreMer-ZEG mouse for genetic lineage mapping; the cardi-
omyocytes of MerCreMer-ZEG mice irreversibly express GFP
upon treatment with 4-OH-tamoxifen, allowing for ‘‘pulse’’
labeling of existing cardiomyocytes (Hsieh et al., 2007). This
lineage-mapping approach has demonstrated that myocardial
infarction or pressure overload results in precursor-dependent
replenishment of the cardiomyocyte pool. Here we used genetic
fate mapping to determine the effect of exogenously delivered
progenitor cells on endogenous cardiomyocyte refreshment.RESULTS
Bone Marrow-Derived c-kit+ Cell Therapy Stimulates
Endogenous Cardiac Progenitors after Myocardial
Infarction
We generated an in-bred transgenic colony of MerCreMer-ZEG
mice over a 4 year period to test the hypothesis that cell
transplantation regulates endogenous progenitor activity. We
assessed the regenerative properties of a purified bone
marrow-derived cell population (lineage/c-kit+ or c-kit+ cells)
previously reported to improve cardiac function (Figure 1A; Orlic
et al., 2001; Rota et al., 2007). MerCreMer-ZEG female mice
were pulsed with 4-OH-tamoxifen to induce cardiomyocyte-
specific GFP expression, after which they were subjected to
myocardial infarction by coronary ligation. Mice were random-
ized to receive vehicle control or c-kit+ cells (63 105) freshly iso-
lated from a wild-type male mouse (Figure S1 available online) in
two divided 5 mL intramyocardial injections to the medial and
lateral infarct borders of the left ventricle. After an 8-week chase,
histologic sections were stained for GFP and b-galactosidase as
previously described (Hsieh et al., 2007). An observer unaware of
treatment group captured photographs from the infarct borderCell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc. 389
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Figure 1. Intramyocardial Delivery of Bone
Marrow-Derived c-kit+ Cells after Myocar-
dial Infarction Stimulates Endogenous
Cardiomyocyte Regeneration
(A) Experimental protocol. MCM+/ZEG+ bitrans-
genic female mice were treated for 2 weeks with
4-OH-tamoxifen (OH-Tam) to induce a cardiomyo-
cyte-specific switch from b-galactosidase (b-gal)
to GFP expression. Experimental MI was per-
formed by coronary ligation. Bone marrow c-kit+
cells, isolated from wild-type (WT) male mice,
were then injected into the peri-infarct region.
The hearts were fixed and stained 8 weeks post-
MI. Also see Figures S1–S3.
(B) Hearts were stained (brown) for GFP (top) or
b-galactosidase (bottom). Representative staining
from the MI border zone. The percentage of GFP+
cardiomyocytes decreased after MI and
decreased further after delivery of c-kit+ cells.
Decrements in the percentage of GFP+ cardio-
myocytes were matched by increases in the
percentage of b-gal+ cardiomyocytes, consistent
with cardiomyocyte repletion by endogenous
b-gal+ progenitors. Scale bars represent 100 mm.
(C and D) Graph representing the percentage of
GFP+ (C) and b-gal+ (D) cardiomyocytes in the MI
border zone and remote areas. Data expressed
as mean ± SEM.
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Cell Therapy Stimulates Endogenous Regenerationzone and remote areas, after which a second blinded observer
counted the positive and negative cardiomyocytes.
As expected, the percentage of GFP+ cardiomyocytes in the
border zone (60.3% ± 1.2%; p < 0.0001) and remote area
(73.3% ± 1.5%; p < 0.01) decreased after myocardial infarction
compared with the sham (80.8% ± 1.8%), consistent with an
increase in progenitor activity stimulated by the injury. However,
c-kit+ cell therapy produced a significant further dilution in the
GFP+ cardiomyocyte pool at the infarct border zone (49.4% ±
2.3%; p < 0.0001) (Figures 1B and 1C), a finding not observed
in either the right ventricle (Figure S2) or regions of the left390 Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc.ventricle remote to the MI. We also
studied b-galactosidase+ cardiomyo-
cytes, because reduction in the GFP+
pool caused by transdifferentiation of
exogenously delivered wild-type c-kit+
cells into mature cardiomyocytes would
not result in a complimentary increase in
b-galactosidase+ cardiomyocytes. The
decrease in GFP+ cardiomyocytes was
balanced by a corresponding increase
in the percentage of b-galactosidase+
cardiomyocytes (Figures 1B and 1D),
consistent with c-kit+ cell-mediated acti-
vation of endogenous progenitors and
not transdifferentiation of the exogenous
c-kit+ cells.
To determine the time frame of the
c-kit+ cell-mediated reduction in GFP+
cardiomyocytes, we also analyzed a
cohort of mice 2 weeks after myocardialinfarction. We found a trend toward a reduction in the
percentage of GFP+ cardiomyocytes 2weeks afterMI (Figure S2;
sham = 80.7% ± 0.5% versus MI = 71.0% ± 3.9%, n.s.). At this
time point, however, there was no additional reduction in the
percentage of GFP+ cardiomyocytes in c-kit+ cell-treated mice,
suggesting that exogenously delivered c-kit+ cells do not exert
their stimulatory effects in the acute post-MI phase.
We performed a study in which c-kit+ cell- or vehicle control-
treated mice also received BrdU (20 mg/hr) by osmotic minipump
for 1 week after MI. Eight weeks after MI, we found that
the majority of BrdU+/troponin+ cardiomyocytes were GFP,
Cell Stem Cell
Cell Therapy Stimulates Endogenous Regenerationa finding consistent with the proliferation and differentiation of
b-galactosidase+ progenitors (Figure S3). We also detected
a significant increase in the number of BrdU+/troponin+ cardio-
myocytes in c-kit+ cell-treatedmice compared to vehicle control,
which is consistent with a c-kit+ cell-stimulated increase in the
generation of new cardiomyocytes.
We also considered the possibility that the reduction in the
percentage of GFP+ cardiomyocytes was due to selective prolif-
eration of b-galactosidase+ cardiomyocytes, as might be ex-
pected if the observed inefficiency in b-galactosidase-to-GFP
recombination was due to a subset of immature cardiomyocytes
with higher proliferative capacity. To address this possibility, we
performed morphometric analyses of b-galactosidase+ and
GFP+ cardiomyocytes, finding that there was no baseline differ-
ence in the size of the two populations (Figure S3). After injury,
however, the GFP+ pool of pre-existing cardiomyocytes was
larger, consistent with compensatory hypertrophy. These data
are consistent with the concept that there are no baseline
differences in the maturity of the b-galactosidase+ and GFP+
cardiomyocytes pools, but after injury, the mean size of the
b-galactosidase+ pool is smaller because it contains newly
differentiated cardiomyocytes.
Cell Therapy with Mesenchymal Stem Cells
after Myocardial Infarction Does Not Stimulate
Endogenous Progenitors
We next sought to test whether the observed stimulation of
progenitors resulted from properties specific to c-kit+ cells. We
used an identical protocol of inducing cardiomyocyte-specific
GFP expression in MerCreMer-ZEG mice and conducted
a randomized, blinded, vehicle-controlled study comparing
c-kit+ cells to bone marrow-derived mesenchymal stem cells
(MSCs), a cell population used in clinical trials and demonstrated
to differentiate into cardiomyocytes in vitro (Hare et al., 2009;
Pijnappels et al., 2008). MSCs were enriched from bone marrow
of wild-type male mice via a standard culture protocol (Beltrami
et al., 2007); the MSC-specific marker profile was reconfirmed
by flow cytometry prior to experimental delivery (Figure S1).
A total of 6 3 105 freshly isolated c-kit+ cells or MSCs were
injected immediately after coronary ligation in MerCreMer-ZEG
female mice.
After an 8week chase, cell therapywith c-kit+ cells again led to
a significant further dilution of the GFP+ cardiomyocyte pool
(56.6% ± 1.7% versus 68.8% ± 1.5%; p < 0.001) and a parallel
increase in the percentage of b-galactosidase+ cardiomyocytes
(42.5% ± 1.8% versus 30.1% ± 1.4%; p < 0.001) compared to
control. However, the delivery of MSCs did not lead to reduc-
tions in GFP+ cardiomyocytes or increases in b-galactosidase+
cardiomyocytes, suggesting that MSCs lacked the ability of
c-kit+ cells to stimulate endogenous progenitor activity (Figures
2A and 2B). Therapy with c-kit+ cells also resulted in a significant
improvement in ejection fraction, a standard measure of cardiac
function (as determined by a blinded cardiac catheterization)
8 weeks after MI (n > 12 mice in each group; p < 0.05; Figure 2C;
Figure S4), consistent with prior rodent and human studies
(Abdel-Latif et al., 2007; Rota et al., 2007). In contrast, MSC
therapy, which did not stimulate endogenous progenitor activity,
did not improve the ejection fraction. The differences in cardiac
function could not be explained by intergroup differences ininfarct size (Figure S4). Although it is possible that the observed
stimulation of endogenous progenitors accounts for the associ-
ated improvements in ventricular function, we cannot exclude
the possibility that additional mechanisms are also involved.
Because of concerns of cardiotoxicity after high-dose tamoxifen
in MerCreMer mice (Koitabashi et al., 2009), we also studied
the effects of our 4-OH-tamoxifen dosing protocol on cardiac
function. Although we were able to induce transient cardiotoxic-
ity with high-dose 4-OH-tamoxifen, we did not observe a similar
effect with our 14-day low-dose protocol (Figure S5). These
experiments suggest that improvements in cardiac function
from specific types of cells, such as c-kit+ cells, may be due to
the ability of these cells to activate endogenous cardiogenic
progenitors.
Cardiomyocyte Transdifferentiation Cannot Explain
the c-kit+ Cell-Mediated Stimulation
of Cardiomyocyte Renewal
We next directly addressed the fate of injected cells to deter-
mine whether the dilution of GFP+ cardiomyocytes could be
explained by either transdifferentiation of exogenously deliv-
ered c-kit+ cells or by their fusion with endogenous cells. We
performed sex-mismatched cell transplantation after MI, deliv-
ering c-kit+ cells or MSCs derived from male MerCreMer-ZEG
mice into female wild-type recipients (Figure 3A). Cell isolation,
purification, and delivery protocols were identical to prior
experiments; 4-OH-tamoxifen was administered between
weeks 6 and 8 after MI to induce GFP expression by any
exogenously delivered MerCreMer-ZEG cells that had transdif-
ferentiated into cardiomyocytes. Eight weeks after MI, we
screened for transdifferentiated cardiomyocytes by performing
GFP and b-galactosidase immunohistochemistry, with 4-OH-
tamoxifen-injected MerCreMer/ZEG mice used as a positive
control. Despite screening multiple sections per mouse and
>10 mice per experimental group, representing more than
7.5 3 105 border zone cardiomyocytes, we found no GFP+ or
b-galactosidase+ cardiomyocytes (Figure 3C). Although this
approach cannot exclude rare cardiomyocyte transdifferentia-
tion by exogenously administered cells, this analysis excludes
with a high degree of certainty (chi-square, p < 0.0001) that
the reduction in the GFP+ cardiomyocyte pool observed in
two independent experiments (Figures 1 and 2) is explained
by transdifferentiation of exogenously administered c-kit+ cells.
For additional confirmation, we performed FISH analysis on
hearts from three independent studies (MSC, 21 mice; c-kit+,
34 mice) and found no Y chromosome-positive nuclei (Fig-
ure 3C), suggesting minimal survival of exogenously delivered
cells in the heart 8 weeks after MI. To confirm successful cell
delivery and further determine the fate of exogenously delivered
cells, we analyzed mice at early time points. Y chromosome-
positive donor cells were easily detected in all hearts 5 min,
24 hr, and 1 week after injection with c-kit+ cells or MSCs
(n = 3 mice/group; Figures 3B and 3C). By 4 weeks after MI,
we no longer could detect Y chromosome+ cells (n = 3 mice),
suggesting substantial loss of exogenously delivered cells
between weeks 1 and 4. Therefore, via multiple independent
methods, the observed stimulation of progenitor activity in
c-kit+ cell-treated mice could not be explained by transdifferen-
tiation of exogenously delivered cells.Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc. 391
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Figure 2. Intramyocardial Delivery of Bone Marrow c-kit+ Cells but Not Bone Marrow-Derived Mesenchymal Stem Cells Stimulates
Endogenous Cardiomyocyte Regeneration
(A) Data are derived from a randomized, blinded studywith the same protocol depicted in Figure 1A and designed to compare the regenerative properties of c-kit+
cells versus mesenchymal stem cells (see Figure S1). After 8 weeks, hearts were fixed and stained (brown) for GFP (top) or b-galactosidase (bottom). Represen-
tative staining from the MI border zone. The percentage of GFP+ cardiomyocytes was again reduced by c-kit+ cells but not MSCs. All decrements in the
percentage of GFP+ cardiomyocytes were matched by increases in the percentage of b-gal+ cardiomyocytes (bottom), consistent with cardiomyocyte repletion
by endogenous b-gal+ progenitors. Scale bars represent 100 mm.
(B and C) Graph representing the percentage of GFP+ (B) and b-gal+ (C) cardiomyocytes in the MI border zone. Data expressed as mean ± SEM.
(D) Graph representing the mean ejection fraction as measured by cardiac catheterization 8 weeks after MI. Data expressed as mean ± SEM.
See Figures S4 and S5.
Cell Stem Cell
Cell Therapy Stimulates Endogenous RegenerationCell Fusion between Donor and Recipient Cells Cannot
Explain the c-kit+ Cell-Mediated Stimulation
of Cardiomyocyte Renewal
Because prior reports have demonstrated fusion between bone
marrow cells and cardiomyocytes (Nygren et al., 2004), we
considered the possibility that cell fusion could explain our find-
ings. Although the absence of Y chromosome+ cardiomyocytes
8 weeks after sex-mismatched cell transplantation made it
unlikely that fusion could account for our findings, we also per-
formed independent experiments to address this possibility.
Either c-kit+ cells or MSCs from MerCreMer/ZEG+ male mice
were delivered to MerCreMer+/ZEG female mice with MI. In
these animals, only cell fusion between donor cells and recipient
cardiomyocytes should result in cells capable of 4-OH-tamox-
ifen-induced Cre-mediated recombination and subsequent
GFP expression. Six weeks after MI, mice were treated with
2 weeks of 4-OH-tamoxifen; we did not identify any borderzone
GFP+ cardiomyocytes, nor did we detect Y chromosome-posi-
tive nuclei in more than 10,000 analyzed cells (n = 4 mice per
group). Although this analysis does not exclude very rare fusion392 Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc.events, it does exclude cell fusion as an explanation for
the observed progenitor activity stimulated by c-kit+ cells
(chi-square p < 0.0001).
Cell Therapy with c-kit+ Cells Increases the Number
of Endogenous Cells Demonstrating Transcriptional
Activity Consistent with Cardiac Progenitors
If exogenously delivered c-kit+ cells stimulate endogenous
progenitors, we hypothesized that one manifestation would be
an increase in the number of cells displaying progenitor character-
istics at the infarct border. We performed a study in which female
mice, undergoing experimental myocardial infarction, were
randomized to receive vehicle control or c-kit+ cells (63 105) iso-
lated from male mice, by intramyocardial injection. Osmotic mini-
pumps delivering bromodeoxyuridine (20 mg/hr) were implanted
subcutaneously at the time of myocardial infarction to allow the
identification of proliferating cells. Mice were sacrificed after
1 week and the tissues were processed for histologic analysis.
We assessed the expression of nkx2.5, GATA4, TBX5, and
Mef2c with immunofluorescent staining of the infarct border
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Figure 3. Cell Therapy-Mediated Cardiomyocyte Regeneration Cannot Be Explained by Transdifferentiation of Exogenously Delivered Bone
Marrow Stem Cells
(A) Experimental protocol. WT female mice underwent experimental MI by coronary ligation prior to the intramyocardial delivery of bone marrow cells isolated
from bitransgenic MCM+/ZEG+ male mice. 6 weeks later, mice were treated for 2 weeks with 4-OH-tamoxifen (OH-tam) prior to sacrifice to induce a b-gal to
GFP switch in expression in any exogenously administered cells that had transdifferentiated into CMs.
(B) Time course of the fate of injected Y chromosome+ c-kit+ cells andMSCs at the MI border zone. Data expressed as Y chromosome+ cells per 100 nuclei. Data
expressed as mean ± SEM.
(C) Representative Y chromosome FISH analysis (green) revealed successful intramyocardial delivery of c-kit+ cells and MSCs in all hearts harvested 5 min or
1 week after intramyocardial injection (12/12). Scale bars represent 10 mm.
(D) GFP and Y chromosome stains from WT mice after MI and intramyocardial delivery of bone marrow cells isolated from bitransgenic mice. The absence of
GFP+ (brown) CMs (top left) suggests that the observed c-kit+ cell-stimulated increase in CM progenitor activity cannot be explained by transdifferentiation of
exogenously delivered cells. Sections from bitransgenic MCM+/ZEG+ mice used as positive controls. By 8 weeks post-MI, Y chromosome+ cells (green) were
no longer detected (bottom left); Y chromosome staining of hearts from male mice used as positive controls (bottom right). Scale bars represent 40 mm.
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Cell Therapy Stimulates Endogenous Regenerationzone, because these transcription factors have been associated
with cardiogenic commitment (Ieda et al., 2010; Molkentin et al.,
1997; Wu et al., 2006; Xin et al., 2006). We excluded troponin
T-positive cardiomyocytes from the analysis, because we were
specifically interested in identifying cells in the progenitor stage
(data not shown). We found a significant increase in the total
number of noncardiomyocyte nkx2.5+ and GATA4+ cells in
mice having been administered c-kit+ cells, compared to vehicle
(Figure 4; nkx2.5, 33.3 ± 6.3 versus 8.1 ± 1.3 per 1000 nuclei;
GATA4, 82.9 ± 10.9 versus 29.3 ± 5.6 per 1000 nuclei, n = 3
mice per group, p < 0.01). We also found a significant increase
in the number of cells coexpressing nkx2.5 and GATA4 (Figure 4;
12.8 ± 2.8 versus 3.8 ± 1.1 per 1000 nuclei, p < 0.01). In contrast,
we found no difference in the frequency of TBX5- or Mef2c-
expressing cells (data not shown). In order to exclude the possi-
bility that cells expressing nkx2.5 and GATA4 were derived
from exogenously delivered c-kit+ cells, we also performed
FISH analysis to identify Y chromosomes. Although we identified
donor-derived Y chromosome-positive cells in all analyzed
sections, the nkx2.5- or GATA4-positive cells were not Y chro-
mosome positive (data not shown). These findings are most
consistent with a c-kit+ cell-mediated increase in cardiacprogenitor number 1 week after myocardial infarction, a finding
that is congruent with the observed c-kit+ cell stimulation of car-
diomyocyte refreshment.
Because resident cardiac c-kit+ cells have been shown to
contribute to endogenous cardiomyocyte regeneration (Beltrami
et al., 2003), we reasoned that if exogenously administered
bone marrow c-kit+ cells were stimulating resident cardiac
c-kit+ cells, there would be a detectable increase in the
frequency of proliferating endogenous c-kit+ cells. We per-
formed c-kit staining at the 1 week time point. We excluded
exogenously administered Y chromosome+/c-kit+ cells from
the analysis and found no increase in the frequency of endoge-
nous border zone c-kit+ cells (data not shown). We also per-
formed a cell therapy experiment with cardiac c-kit+ cells iso-
lated from MerCreMer-ZEG mice delivered by intramyocardial
injection to wild-type mice after MI. 4-OH-tamoxifen was admin-
istered for 2 weeks prior to sacrificing the mice a total of 4 weeks
after MI. We detected no b-galactosidase+ or GFP+ cardiomyo-
cytes (data not shown). Taken together, these data argue
against the concept that cell therapy with bone marrow c-kit+
cells exerts proregenerative effects by stimulating resident
c-kit+ cells.Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc. 393
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Figure 4. c-kit+ Cell Therapy Leads to Increased Numbers of Cardiac Progenitors after Myocardial Infarction
(A and B) Immunofluorescent staining with a representative cluster of proliferating GATA4+ (A) and nkx2.5+ (B) cells.
(C) Immnofluorescent staining representing a subset of coexpressing nkx2.5+ and GATA4+ cells.
Scale bars represent 10 mm.
(D) Bar graph depicting an increase in the number of infarct border zone GATA4+ cells in mice treated with c-kit+ cells compared to vehicle control. The BrdU+
fraction is denoted by red bars. Data are expressed as total number of noncardiomyocyte GATA4+ cells per 1000 nuclei (n = 3 animals per group). Only troponin
T-negative noncardiomyocytes were counted. Data expressed as mean ± SEM.
(E) Bar graph depicting an increase in the number of infarct border zone nkx2.5+ cells in mice treated with c-kit+ cells compared to vehicle control. The BrdU+
fraction is denoted by red bars. Data are expressed as total number of noncardiomyocyte nkx2.5+ cells per 1000 nuclei (n = 3 animals per group). Only troponin
T-negative noncardiomyocytes were counted. Data expressed as mean ± SEM.
(F) Bar graph depicting an increase in the number of infarct border zone coexpressing nkx2.5+/GATA4+ cells in mice treated with c-kit+ cells compared to vehicle
control. The BrdU+ fraction is denoted by red bars. Data are expressed as total number of noncardiomyocyte GATA4+/nkx2.5+ cells per 1000 nuclei (n = 3 animals
per group). Only troponin T-negative noncardiomyocytes were counted. Data expressed as mean ± SEM.
Cell Stem Cell
Cell Therapy Stimulates Endogenous RegenerationLocal Delivery of SDF-1 Does Not Stimulate
Cardiomyocyte Progenitors
Because paracrine factors have been proposed as a mechanism
of benefit of cardiac cell therapy, and because c-kit+ cell-medi-
ated production of a proregenerative paracrine factor could
account for the observed activation of endogenous progenitors,
we asked whether local administration of the stem cell chemo-394 Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc.kine, SDF-1a, can stimulate endogenous progenitor activity. To
test this hypothesis, we used a protease-resistant form of
SDF-1a that we previously demonstrated to facilitate sustained
local delivery after intramyocardial delivery (Segers et al.,
2007). We performed a randomized, blinded, vehicle-controlled
study in MerCreMer-ZEG mice to test the hypothesis that
sustained delivery of SDF-1a can activate cardiomyocyte
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Figure 5. c-kit+ Cell-Mediated Stimulation of Endogenous Cardiomyocyte Progenitor Activity Cannot Be Recapitulated by Local Delivery
of the Stem Cell Chemoattractant, Stromal-Derived Factor-1a
(A) Local delivery of SDF-1 stimulates neovascularization at theMI border zone. Representative images of isolectin staining in theMI border zone 8weeks after MI
and the administration of vehicle control (top), nanofibers (middle), or nanofibers and SDF-1 (bottom). Scale bars represent 20 mm.
(B) Graph representing the number of isolectin+ vessels in the MI border zone per mm2. Representative of two independent, randomized, double-blinded
experiments. Data expressed as mean ± SEM.
(C) Graph representing the percentage of GFP+ cardiomyocytes in the MI border zone. Local delivery of SDF-1 does not change the percentage of GFP+ CMs in
the MI border zone compared to nanofibers alone or vehicle control. Data expressed as mean ± SEM.
(D) Graph representing the percentage of b-gal+ cardiomyocytes in the MI border zone. Data expressed as mean ± SEM.
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Cell Therapy Stimulates Endogenous Regenerationprogenitors. Although SDF-1a stimulated neovascularization as
predicted (Figures 5A and 5B), the percentage of GFP+ or
b-galactosidase+ cardiomyocytes was unchanged (Figures 5C
and 5D), suggesting that SDF-1a cannot recapitulate the
progenitor-activating effect of c-kit+ cells. It is possible that
c-kit+ cells deliver many paracrine signals or that SDF-1a can
benefit cardiac function through a mechanism distinct from cell
therapy.
DISCUSSION
There have been intense efforts to develop cellular therapies to
treat human heart failure, but the mechanism of action of cardiac
cell therapies has remained unclear (Hansson et al., 2009). Many
possible explanations for cell therapy-mediated improvements
in cardiac function have been proposed, including direct
transdifferentiation of exogenously delivered cells into cardio-
vascular cells, cell therapy-mediated cardioprotection, and
paracrine stimulation of angiogenesis or endogenous progeni-
tors (Dimmeler et al., 2005). The current study was prompted
by the recognition that optimization of cell therapies will require
an understanding of the mechanisms responsible for cardiac
functional improvements. Here, we used a genetic lineage-
mapping approach to determine the effect of bone marrow-derived cell therapy on the endogenous regenerative response.
We chose to study bonemarrow-derived c-kit+ cells andmesen-
chymal stem cells because these cell types have been attributed
cardiogenic properties and similar preparations have been used
in human clinical trials (Abdel-Latif et al., 2007).
The central finding of this study is that cell therapy with c-kit+
bone marrow progenitors after experimental myocardial
infarction activates endogenous cardiac progenitors. The
MerCreMer-ZEG transgenic mouse provides an indirect
measure of progenitor activity when the pre-existing GFP-
labeled cardiomyocyte pool is diluted by differentiation of unla-
beled cardiomyocyte progenitors. An important advantage of
this approach is that it detects cumulative progenitor activity
and is not dependent upon the identification of the anatomic
source or of the transcriptional phenotype of the master cardiac
progenitors, both of which remain unresolved issues in the field
(Hansson et al., 2009). Moreover, although others have
proposed endogenous progenitor activation as a mechanism
of benefit from cell therapy (Tang et al., 2010), our study repre-
sents the demonstration of this process with the powerful
approach of genetic lineage mapping.
We did not detect direct cardiomyocyte transdifferentiation by
exogenously administered bone marrow progenitors, as was
first demonstrated by Orlic and colleagues (Orlic et al., 2001).Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc. 395
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Cell Therapy Stimulates Endogenous RegenerationAlthough our analysis cannot rule out rare transdifferentiation,
we can conclude that transdifferentiation cannot account for
the c-kit+ cell-stimulated cardiomyocyte repletion observed in
this study. Our results suggest that transdifferentiation under
these circumstances is probably very rare, as others have sug-
gested (Balsam et al., 2004; Murry et al., 2004). We speculate,
as have others, that interstudy differences have led to variations
in the observedmagnitudes of the direct regenerative capacity of
bone marrow progenitors (Laflamme and Murry, 2005).
Genetic fate mapping is an important approach to tracking cell
fate, but there are important considerations to cardiomyocyte
turnover to consider in these experiments. We cannot definitively
exclude the possibility that the c-kit+ cell-mediated reduction in
the percentage of GFP+ cardiomyocytes is a result of either
selective loss of GFP+ cardiomyocytes or selective proliferation
by a subset of immature b-galactosidase+ cardiomyocytes,
rather than cardiomyocyte repletion by GFP progenitors. The
cumulative evidence, however, suggests that our central finding
is not an artifact of either selective cell death or proliferation.
We have previously shown that GFP+ cardiomyocytes in the
MerCreMer-ZEG mouse do not exhibit a heightened sensitivity
to apoptosis after myocardial infarction (Hsieh et al., 2007). In
the current study, in the absence of injury, we did not detect
a size difference between GFP+ and b-galactosidase+ popula-
tions as might be expected if b-galactosidase+ cardiomyocytes
were immature. Furthermore, the improvement in cardiac func-
tion associated with c-kit+ cell therapy coupled with a c-kit+
cell therapy-mediated increase in the number of nkx2.5- and
GATA4-positive cells after MI lends further support to our
conclusion that c-kit+ cell therapy stimulates proregenerative
activity by endogenous cardiomyocyte progenitors rather than
proliferation of pre-existing cardiomyocytes as has been demon-
strated in nonmammalian organisms (Bersell et al., 2009; Kikuchi
et al., 2010). Ultimately, further experiments in different experi-
mental models and in human tissues via methods with separate
limitations and capabilities will be necessary for a definitive
picture of cardiomyocyte refreshment in mammalian
myocardium.
The observed benefits of c-kit+ cell therapy in our study were
contrasted by the absence of an effect of mesenchymal stem cell
therapy on endogenous progenitors, although this study cannot
exclude the possibility that mesenchymal stem cells have addi-
tional beneficial properties. We speculate that the inconsistent
effects of cell therapies in both animal and human studies may
in part be attributable to specific cell preparations and their
capacity to activate endogenous progenitors. Elucidating
factor(s) that enable certain cell populations, like bone marrow-
derived c-kit+ cells, to stimulate endogenous progenitors may
facilitate optimization of cell therapy for the heart, a prerequisite
to widespread clinic application.
Understanding the mechanisms underpinning the proregener-
ative properties of c-kit+ cells could provide noncellular therapies
in the future. If, as suggested by our study, exogenously deliv-
ered c-kit+ cells exert regenerative effects by releasing a para-
crine signal to endogenous progenitors, it may be possible to
stimulate endogenous regeneration pharmacologically. In the
current study, we tested one such paracrine candidate, SDF-
1a. Although a number of soluble factors have been attributed
regenerative properties, SDF-1a represents a particularly attrac-396 Cell Stem Cell 8, 389–398, April 8, 2011 ª2011 Elsevier Inc.tive candidate because of its capacity to both recruit a wide
variety of stem cell populations and improve cardiac function
after ischemic injury (Ceradini et al., 2004; Saxena et al., 2008;
Segers et al., 2007; Zaruba et al., 2009). As previously demon-
strated, SDF-1a stimulated neovascularization at the MI border
but did not appear to stimulate endogenous cardiomyocyte
progenitors as previously hypothesized (Segers et al., 2007).
In summary, intramyocardial delivery of c-kit+ bone marrow
cells after MI induces endogenous progenitor-derived cardio-
myocytes and improves ventricular function, an effect not
observed with MSCs. With multiple methods, these effects of
c-kit+ cells could not be explained by their direct transdifferentia-
tion into cardiomyocytes. The c-kit+ cell-mediated activation of
endogenous progenitors may depend on paracrine communica-
tion between donor and recipient cells. Understanding why
specific cell types have the potential to stimulate endogenous
cardiac progenitors may enable the future development of phar-
macoregenerative therapies as well as improving current cell
therapy strategies.EXPERIMENTAL PROCEDURES
Generation and Maintenance of MerCreMer-ZEG Colony
Double transgenic MerCreMer-ZEG mice were generated by cross-breeding
transgenic B6129-Tg(Myh6-cre/Esr1)1Jmk/J (MerCreMer) mice with the
B6.Cg-Tg(ACTB-Bgeo/GFP)21Lbe/J reporter strain (ZEG, Jackson Laborato-
ries) as previously described. Genotyping was performed by PCR on tail DNA
with the following primers: MerCreMer forward: 50-GTCTGACTAGGTGT
CCTTCT-30; MerCreMer backward: 50-CGTCCTCCTGCTGGTATAG-30; ZEG
forward: 50-AAGTTCATCTGCACCACCG-30; ZEG backward: 50-TCCTTGAAG
AAGATGGTGCG-30; ZEG control forward: 50-CTAGGCCACAGAATTGAAAGA
TCT-30; and ZEG control backward: 50-GTAGGTGGAAATTCTAGCATCAT
CC-30. Mice used for cell transplantation experiments were derived from
a transgenic colony subjected to inbreeding for >4 years and >30 generations.
Maintenance of the colony and all experiments were conducted in accordance
with the Guide for the Use and Care of Laboratory Animals and approved by
the Harvard Medical School Standing Committee on Animals.4-OH-Tamoxifen Pulse
A previously validated protocol was used to induce Cre recombinase-medi-
atedGFP expression and permanent deletion of b-galactosidase gene expres-
sion in the cardiomyocytes of MerCreMer-ZEG mice. 4-OH-tamoxifen
(provided by a generous gift from Laboratoires Besins) was dissolved in peanut
oil (Sigma) at a concentration of 5 mg/mL and injected intraperitoneally at
a dose of 20 mg/kg/d for 2 weeks. The same dosing schedule was adminis-
tered to wild-type mice, 6 weeks after treatment with bone marrow stem cells
derived from MerCreMer-ZEG bitransgenic mice.Experimental Myocardial Infarction and Cellular Delivery
Mice were subjected to experimental myocardial infarction as described.
Surgeries were performed by a single operator with more than 20 years of
experience in the performance of coronary ligation in rodents. In brief, the
left coronary artery was permanently ligated approximately 2 mm below the
left atrial appendage. For sham operations, the thoracic cavity was opened
and the heart exposed, but no intramyocardial sutures were placed. All intra-
myocardial injections (cells, vehicle control, or protein therapy) were per-
formed immediately after coronary ligation, prior to closure of the thoracic
cavity. 5 ml injections with a 31 g syringe (Hamilton) were administered to the
medial and lateral infarct border regions (total of two injections per mouse).
BrdU (Sigma) was administered at a rate of 20 mg/hr experiments via osmotic
minipump (Alzet), implanted subcutaneously at the time of experimental
myocardial infarction.
Cell Stem Cell
Cell Therapy Stimulates Endogenous RegenerationBone Marrow Stem Cell Isolation
c-kit+ bone marrow cells were isolated via immunomagnetic sorting (Miltenyi
Biotec). Bone marrow was harvested from the femurs and tibias of adult
male mice (aged 8–12 weeks). Marrow was suspended in PBS containing
0.5% BSA and 2 mM EDTA. The cell suspension was first depleted of lineage+
cells (expressing the following cell surface antigens: CD5, CD45R [B220],
CD11b, Gr-1 [Ly-6G/C], 7-4, and Ter-119) prior to positive selection for c-kit
expression. This system yielded a cellular preparation of >97% c-kit+ cells
assayed by flow cytometry (Figure S1). Bonemarrowmesenchymal stem cells
were isolated from adult mice (aged 8–12 weeks) and grown in hypoxic condi-
tions (1% O2) with Mesencult medium/protocol (Stem Cell Technologies).
Mesenchymal stem cells used for cell therapy were taken from passages
7–9. For all experiments in which MSCs were delivered therapeutically, the
mesenchymal stem cell surfacemarker profile was verified with flow cytometry
one passage prior to cell administration. Both c-kit+ cells and MSCs were
resuspended in unsupplemented DMEM (vehicle) and placed on ice prior to
intramyocardial delivery. Cells were administered within 3 hr of isolation
(c-kit+ cells) or harvest from the culture flask (MSCs). A total of 6 3 105 cells
were delivered per mouse in two divided injections.
Immunohistochemistry and Immunofluorescent Microscopy
Mouse hearts were fixed with 4% paraformaldehyde, paraffin embedded,
sectioned, and stained with standard immunohistochemistry and fluorescent
microscopy methods as previously described. An antigen retrieval step was
used in all experiments, by heating samples in a citrate-based buffer (Dako)
to 95C for 20 min. Primary antibodies were used as follows: rabbit GFP-
specific antibody 1:400 (Abcam); rabbit b-galactosidase-specific antibody
1:200 (Invitrogen); mouse troponin T-specific antibody 1:200 (Abcam); rat
BrdU-specific antibody 1:200 (Abcam); rabbit nkx2.5-specific antibody 1:50
(Abcam); goat nkx2.5-specific antibody 1:50 (Santa Cruz); rabbit GATA4-
specific antibody 1:50 (Santa Cruz); rabbit Mef2c-specific antibody 1:200
(Abcam); rabbit TBX5-specific antibody 1:400 (Abcam); rabbit c-kit-specific
antibody 1:50 (Santa Cruz); and Isolectin 1:200 (Invitrogen). Alexa-Fluor (Invi-
trogen) secondaries were used at 1:200 dilution for all immunofluorescence.
A biotinylated anti-rabbit secondary followed by ABC reagent and DAB (Vector
Laboratories) were used for immunohistochemistry.
In Situ Hybridization
To probe for Y chromosomes, sections were incubated in 1 M sodium thiocy-
anate for 10min at 80C, washed in PBS, and digested in 0.4% pepsin in 0.1M
HCl at 37C. Sections were quenched in 0.2% glycine in 23 PBS, rinsed in 13
PBS, postfixed in 4% paraformaldehyde/PBS, dehydrated through graded
ethanol, and air-dried. Biotinylated-labeled Y chromosome paint (Star-FISH,
Cambio) was suspended in hybridization mix, applied to sections, and sealed
under glass with rubber cement. Samples were heated to 60C for 10 min.
After an overnight incubation at 37C, slides were washed three times with
50% formamide/23 standard saline citrate, three washes with 23 standard
saline citrate, and two washes with 43 standard saline citrate/0.1% TWEEN,
all at 37C. Samples were blocked with PBS/10% horse serum and incubated
for 2 hr in streptavidin-conjugated Alexa Fluor 488 (Invitrogen). Any immunoflu-
orescent staining was performed prior to digestion. Sections were photo-
graphed at the completion of immunofluorescent staining and again after
in situ hybridization. Images were aligned with Adobe Photoshop.
Flow Cytometry
All flow cytometry was performed on fresh, unfixed cells kept on ice during all
incubation steps. Cells were blocked with PBS/0.5% BSA for 10 min prior to
resuspension at a concentration of 1 3 106 cells per 250 mL. Cells were incu-
bated for 30 min in directly conjugated primary antibodies specific for PE-c-kit
(eBioscience), PE-sca-1 (eBioscience), PE-CD105/endoglin (eBioscience),
PE-CD45 (Miltenyi), FITC-CD31 (eBioscience), and PE-CD166 (eBioscience),
washed twice in PBS, prior to flow analysis. Conjugated isotype control anti-
bodies were used in all experiments.
Cardiac Function Assessment
Hemodynamic parameters were acquired with the close-chest invasive
method with a Millar Pressure Volume Catheter (Millar Instruments) through
the right carotid artery. Hemodynamic tracings were analyzed by PowerLabChart5 (ADInstruments). Serial echocardiography was performed by a single
operator. All data were acquired and analyzed by an operator whowas blinded
to treatment assignment.
Study Design
Treatment assignments for cell therapy and protein studies were made
by randomization. Both the operator who performed the surgeries and intra-
myocardial injections and the operative assistant charged with drawing up
therapies for intramyocardial injection were blinded to the identity of the
administered agent.
Image Analysis
After sections were stained for GFP or b-galactosidase, images were captured
by an observer blinded to all experimental information. For each animal,
images were captured from a section taken from two independent levels
(mid-ventricle and mid-apical) by a photographer blinded to experimental
information. Four images were taken from the remote area, defined as tissue
from the posterior wall of the left ventricle. Four images were also taken
from the MI border zone defined as an image not farther away than one
high-power field from scar tissue but not including the scar. Positive and nega-
tive cardiomyocytes were counted in each image by an independent observer,
also blinded to experimental information. Only cells with clear cardiomyocyte
morphology were included. The denominator was taken as the sum of nega-
tively and positively stained cells. Isolectin-positive vessels were also photo-
graphed and analyzed by an observer blinded to experimental information.
The number of isolectin-positive vessels per mm2 was quantitated in the MI
border zone by selecting areas in which the majority of vessels were displayed
in cross-section. Vessels were counted with automated software (ImageJ).
Infarct size was determined by the midline method with trichrome-stained
(Sigma) sections taken from multiple ventricular levels (Takagawa et al.,
2007). Border zone cardiomyocyte cross-sectional area was determined by
averaging a minimum of 50 cardiomyocytes per animal by an observer
unaware of experimental group. Suitable cross-sections were defined as
having circular capillary profiles and circular myocyte sections.
Statistical Analyses
Data comparing the rates of GFP+ or b-galactosidase+ cardiomyocytes
(Figures 1, 2, and 5; Figure S2), the number of nkx2.5+ or GATA4+ cells (Fig-
ure 4), vessel density (Figure 5), or functional data (Figure 2; Figures S4 and
S5) were subjected to one-way ANOVA and posthoc Bonferonni correction.
Statistical significance was assigned for p < 0.05; results are shown with
standard estimate of the mean.
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